Burak Karakaş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Burak Karakaş has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ali Şahin
SİVAS CUMHURİYET ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication Ali Şahi̇n
1 shared publication- Beliz Karataş
Sivas Cumhuriyet Üniversitesi
1 shared publication - Fatih Albayrak
Department of Rheumatology, Gaziantep University, 27310 Gaziantep, Turkey
1 shared publication - Mehmet Emin Derin
Department of Internal Medicine, Rheumatology Unit, Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
1 shared publication - Neşe Çabuk Çelik
Department of Rheumatology, Sincan Training and Research Hospital, Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
- 1 July 2021
- Published by Cumhuriyet Medical Journal in Cumhuriyet Medical Journal
- Vol. 43 (2) , 177-181
Paradoxically Psoriasis, developed in a patient using adalimumab for ankylosing spondylitis: Case report
Anti-tumor necrosis factor agents are effective drugs for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Although it is indicated for the treatment of Ankylosing Spondylitis, there are recent publications about paradoxical side effects due to these agents, mostly in the form of case reports. In this article, we present the psoriasis case that develops paradoxically in a patient with ankylosing spondylitis using adalimumab.
- 1 July 2021
- Published by Cumhuriyet Medical Journal in Cumhuriyet Medical Journal
- Vol. 43 (2) , 177-181
Open AccessParadoxically Psoriasis, developed in a patient using adalimumab for ankylosing spondylitis: Case report
Anti-tumor necrosis factor agents are effective drugs for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Although it is indicated for the treatment of Ankylosing Spondylitis, there are recent publications about paradoxical side effects due to these agents, mostly in the form of case reports. In this article, we present the psoriasis case that develops paradoxically in a patient with ankylosing spondylitis using adalimumab.
- Open Access
- 30 January 2020
- Published by Springer Nature in Advances in Rheumatology
- Vol. 60 (1) , 1-7
Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
İntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis. Methods: Between January 2014 and March 2019, 65 patients following-up at Sivas Cumhuriyet University (Medical Faculty Rheumatology-Internal Medicine Department) who were diagnosed with FMF according to the criteria of Tel-Hashomer were included in the study. The laboratory values and clinical features of patients and disease activities were recorded at least every 3 months, and these data were analyzed. Results: Forty-one (63.1%) patients used anakinra (100 mg/day) and 24 (36.9%) patients used canakinumab (150 mg/8 week). The median duration of anti-IL-1 agents use was 7 months (range, 3–30). Fifteen (23.1%) cases were complicated with amyloidosis. Seven (10.8%) patients had renal transplantation. Overall, the FMF 50 score response was 96.9%. In the group that had a glomerular filtration rate (GFR) ≥ 60 ml/min/m2, the median proteinuria decreased from 2390 mg/day (range, 1400–7200) to 890 mg/day (range, 120–2750) (p = 0.008). No serious infections were detected, except in one patient. Conclusions: Anti-IL-1 agents are effective and safe in the treatment of FMF patients. These agents are particularly effective at reducing proteinuria in patients with GFR ≥ 60 ml/min/m2, but less effective in cases with FMF associated with arthritis and sacroiliitis. Large and long follow-up studies are now needed to establish the long-term effects of these treatments.
- 30 January 2020
- Published by Springer Nature in Advances in Rheumatology
- Vol. 60 (1) , 1-7
Open AccessAssessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
İntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis. Methods: Between January 2014 and March 2019, 65 patients following-up at Sivas Cumhuriyet University (Medical Faculty Rheumatology-Internal Medicine Department) who were diagnosed with FMF according to the criteria of Tel-Hashomer were included in the study. The laboratory values and clinical features of patients and disease activities were recorded at least every 3 months, and these data were analyzed. Results: Forty-one (63.1%) patients used anakinra (100 mg/day) and 24 (36.9%) patients used canakinumab (150 mg/8 week). The median duration of anti-IL-1 agents use was 7 months (range, 3–30). Fifteen (23.1%) cases were complicated with amyloidosis. Seven (10.8%) patients had renal transplantation. Overall, the FMF 50 score response was 96.9%. In the group that had a glomerular filtration rate (GFR) ≥ 60 ml/min/m2, the median proteinuria decreased from 2390 mg/day (range, 1400–7200) to 890 mg/day (range, 120–2750) (p = 0.008). No serious infections were detected, except in one patient. Conclusions: Anti-IL-1 agents are effective and safe in the treatment of FMF patients. These agents are particularly effective at reducing proteinuria in patients with GFR ≥ 60 ml/min/m2, but less effective in cases with FMF associated with arthritis and sacroiliitis. Large and long follow-up studies are now needed to establish the long-term effects of these treatments.